Objectives: Open fetal surgery became standard of care for myelomeningocele (MMC) after the MOMS trial and have encouraged many centres to enable them to be performed this procedure and broadening their indications. We reviewed the outcomes from our centre for MMC repair and others fetal conditions including data from surgery and perinatal period. Methods: A total of 211 open fetal surgeries were performed including 203 myelomeningoceles according MOMS criteria; Encephalocele (4); Congenital high airway obstruction syndrome (2); Congenital cystic adenomatoid malformation (1) and cervical myelomeningocele (1) using an alternative surgical approach developed in our institution during the last five years. The surgeries were undertaken with the same team with expertise in open fetal surgical and prepared to handle maternal and fetal complications. Results: All procedures were performed as scheduled and there was no maternal death. Myelomeningocele: GA at surgery 25 weeks (24-26); Surgery time 117 minutes (106-148); Interval between surgery and birth 52.9 days (5-89); Preterm labour 17.1%; PROM 20.6%; Placental abruption 1.0%; Dehiscence of uterine suture 3.5%; GA at delivery 34 weeks (26-37); GA <30 weeks 6.0%; Weight 2,210g (680-3,515); Perinatal death 1,9%; Reversal of hindbrain herniation at birth 72.9% and ventriculoperitoneal shunt insertion 2.5%. Other fetal anomalies: GA at surgery 25 weeks (24-27); Surgery time 141 minutes (113-168); Interval between surgery and birth 48.6 days (7-71); Preterm labour 25%; PROM 37.5%; GA at delivery 33 weeks (25-36); GA <30 weeks 12.5%; Weight 2,138g (1, 035 Objectives: Incidental finding of asymptomatic endometrial polyps is common. 44.4% of polyps in premenopausal women and 36.1% in postmenopausal women are asymptomatic. Pre-malignant or malignant changes are only found in 1.7% premenopausal and 5.4% postmenopausal women. These changes are less common in asymptomatic women in whom expectant management could be a safe management option. The main objective of this study was to assess the change in polyp's size and the development of abnormal bleeding in women who were managed expectantly. Methods: We retrospectively searched our ultrasound clinic database between July 1997 and September 2015 to identify women aged ≥18 years with endometrial polyp that were managed expectantly for ≥6 months. All women were examined at least twice by a single expert ultrasound operator with a minimum interval of 6 months between the examinations. We excluded women who were using hormonal contraception, HRT or medication that affected the endometrium such as tamoxifen. Results: 3008 women were diagnosed with endometrial polyps between July 1997 and September 2015. Among them, 112 women met inclusion criteria. Mean age of women at initial scan was 54.1 years (range, 25-93) . 67/112 (60%) women were postmenopausal. Median examination interval between initial and final scans was 22.5 months (range, 6-136); majority of women (104/112, 93%) had a single polyp. 75/112 (67%) women were initially asymptomatic of abnormal uterine bleeding. 11/75 (15%) women later developed abnormal bleeding during follow-up period. Patients' age, presence of a pedicle vessel on Doppler examination, polyps' size or growth rate were not predictive of women who would become symptomatic. 7/112 (6.3% (95% CI 1.8-10.7)) had spontaneous complete regression of polyp. Conclusions: Our study did not find that it was useful to routinely monitor asymptomatic endometrial polyps which appeared benign on ultrasound, as the change in polyp's size was not predictive of future development of abnormal bleeding; a small proportion of polyps also undergo spontaneous regression.
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Non-atypical endometrial hyperplasia: clinical and sonographic characteristics and long-term outcome Objectives: To assess clinical and sonographic findings and cancer risk of patients with non-atypical endometrial hyperplasia (NEH) in women with postmenopausal bleeding. Methods: A retrospective analysis of women, age 55 and older, who underwent endometrial sampling between 1997 and 2008. The study group included patients with current or prior confirmed diagnosis of NEH. The women were followed through 2015 for long term clinical outcome. Clinical and sonographic data was analysed and compared between the study group and all other cases with benign endometrial pathology. P<0.05 was considered statistically significant. Results: 1808 women were included in the study with mean age of 64.5 (55 to 96 years). Mean surveillance time was 11.0+/-2.7 years (range: 6.3-17.8). Pathology breakdown showed: 123 (6.8%) cases of endometrial cancer, 20 (1.1%) complex atypical hyperplasia and 73 (4.0%) NEH (51 of the cases were newly diagnosed and 22 had a prior diagnosis of NEH). 26/73(35.6%) had non-atypical complex hyperplasia (NCH) and 47 (64.4%) had simple hyperplasia (SH). Women with NEH had similar age and significantly higher BMI compared to the rest of the patients (63.4% vs. 64.2% p=0.85 and 33.9 vs. 31.4, P=0.01 respectively). On ultrasound, the mean endometrial thickness (EE) of the study group was 11.1mm (1-30mm). 5 women had EE < 5mm but none of them developed cancer.
During long-term surveillance of NEH: 7 (9.6%) cases developed endometrial cancer, 1 (1.4%) developed complex atypical hyperplasia and 16 had persistent NEH (21.9%). 50.4% underwent surgical intervention (67.6% had a hysterectomy).
During long term surveillance of SH subgroup: 3 (6.4%) cases developed cancer and 9 (19.1%) had persistent NEH. 44.7% underwent surgical intervention (57.1% had a hysterectomy).
Conclusions:
In our study population of women 55 years and older, NEH is associated with a significant progression to endometrial cancer, persistent hyperplasia and future surgical intervention.
Sonography performed well in excluding cases of future cancer, but not as well in excluding hyperplasia.
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Risk of endometrial cancer in asymptomatic postmenopausal women with endometrial thickness >11mm: systematic review and meta-analysis Obstetrics and Gynecology, Fundación Jiménez Diaz, Madrid, Spain Objectives: To evaluate the risk of endometrial cancer (EC) and/or endometrial hyperplasia with atypia (EHA) in asymptomatic postmenopausal women with endometrial thickness ≥11mm. Methods: Systematic review of literature using database search (Pubmed, Web of Science and Google Scholar) of articles published between January 2000 and December 2016 evaluating the correlation between endometrial thickness as measured by transvaginal ultrasound(double layer) and histopathological findings in asymptomatic postmenopausal women, using the following terms: ''endometrial thickness", ''postmenopausal", ''postmenopause" and ''asymptomatic". Inclusion criteria were prospective or retrospective studies of more than 150 cases that provided information on endometrial thickness and its correlation with histopathological data. Studies that included patients with hormone replacement therapy, tamoxifen, SERMs and/or aromatase inhibitors were excluded. The overall relative risk (RR) for EC/EHA was calculated, stratifying the patients into two groups according to endometrial thickness (<11mm and ≥11mm). Heterogeneity was assessed by calculating I 2 .
Results:
The search identified 503 studies. After reading title and abstract, 462 articles were discarded. Full text of 41 articles was reviewed, of which 33 were discarded and 8 articles that met all the inclusion criteria were finally selected for evaluation. A total of 4382 women were included. The prevalence of EC/HEA was 0.03% (72 cases). The relative risk of EC/EHA in the ≥11mm group was 3.1 (95% CI: 1.5-6.4). Moderate heterogeneity was observed between studies (I2: 44.6%, p = 0.08).
Conclusions:
The risk of EC/HEA in asymptomatic postmenopausal women with endometrial thickness ≥11mm is three times greater than in women with endometrial thickness <11mm. The indication of endometrial biopsy in these cases seems justifiable.
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Intra-and interobserver agreement using the MUSA terminology for ultrasonographic features associated with ill-defined lesions 
